NasdaqGM - Delayed Quote USD

Biora Therapeutics, Inc. (BIOR)

Compare
3.3494 -0.0806 (-2.35%)
At close: November 1 at 4:00 PM EDT
3.4200 +0.07 (+2.11%)
After hours: November 1 at 5:07 PM EDT
Loading Chart for BIOR
DELL
  • Previous Close 3.4300
  • Open 3.4400
  • Bid 3.2100 x 100
  • Ask 3.4400 x 100
  • Day's Range 3.3100 - 3.4786
  • 52 Week Range 3.3100 - 19.9000
  • Volume 27,436
  • Avg. Volume 38,924
  • Market Cap (intraday) 12.318M
  • Beta (5Y Monthly) 1.23
  • PE Ratio (TTM) --
  • EPS (TTM) -49.3000
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 97.50

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

www.bioratherapeutics.com

58

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIOR

View More

Performance Overview: BIOR

Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIOR
75.19%
S&P 500
20.10%

1-Year Return

BIOR
82.78%
S&P 500
36.60%

3-Year Return

BIOR
99.63%
S&P 500
24.39%

5-Year Return

BIOR
99.91%
S&P 500
84.93%

Compare To: BIOR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIOR

View More

Valuation Measures

Annual
As of 11/1/2024
  • Market Cap

    12.32M

  • Enterprise Value

    53.95M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    17.35

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    62.74

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -125.06%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    860k

  • Net Income Avi to Common (ttm)

    -86.81M

  • Diluted EPS (ttm)

    -49.3000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.33M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -19.18M

Research Analysis: BIOR

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 318k
Earnings 6.46M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

45.00
97.50 Average
3.3494 Current
150.00 High
 

Company Insights: BIOR

People Also Watch